๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shijiazhuang
Clinical trial register · China

Clinical Trials in Shijiazhuang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shijiazhuang 43 Hebei 1
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hebei Medical University Fourth Hospital43 Novartis Pharmaceuticals12 BeOne Medicines9 Beijing InnoCare Pharma Tech Co., Ltd.8 Bristol-Myers Squibb8 Clear sponsor filter
Site location
Shijiazhuang43 Hebei1
All 2 locations
Target enrolment
to

Trials with a site in Shijiazhuang

43 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07823270Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
33
Shijiazhuang
2026-10
Recruiting
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma
NCT07744932Oligometastatic Clear Cell Renal Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
48
Shijiazhuang
2026-08-15
Not yet open
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
NCT07697040Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 1
12
Shijiazhuang
2026-07-01
Not yet open
A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction
NCT07607210Siewert Type II Adenocarcinoma of the Esophagogastric Junction
Hebei Medical University Fourth Hospital
Phase 2
38
Shijiazhuang
2026-06-01
Not yet open
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
NCT07585279Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
Hebei Medical University Fourth Hospital
Phase 2/3
408
Shijiazhuang
2026-05-20
Not yet open
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
NCT07528898Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2
100
Shijiazhuang
2026-05
Recruiting
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
NCT07448077Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
Hebei Medical University Fourth Hospital
Phase 2
128
Shijiazhuang
2026-03-01
Not yet open
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
NCT07410611Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
Hebei Medical University Fourth Hospital
Phase 2
84
Shijiazhuang
2026-02-10
Recruiting
Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study
NCT07669493MACE, Arrhythmia, Pericardial Effusion and Survival
Hebei Medical University Fourth Hospital
Observational
150
Shijiazhuang
2026-01-17
Recruiting
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
NCT07289997AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC, Immunotherapy
Hebei Medical University Fourth Hospital
Phase 2
39
Shijiazhuang
2025-09-28
Recruiting
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
NCT07290010Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital
Phase 2
25
Shijiazhuang
2025-09-26
Recruiting
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
NCT07131007Malignant Neoplasm, Organ Damage
Hebei Medical University Fourth Hospital
Observational
2,000
Shijiazhuang
2025-09-15
Recruiting
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
NCT07492394Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-09-12
Recruiting
Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
NCT07266480Squamous Oesophageal Cancer
Hebei Medical University Fourth Hospital
Phase 2
142
Shijiazhuang
2025-09-01
Not yet open
A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
NCT07112833Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
36
Shijiazhuang
2025-08-10
Not yet open
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study
NCT07004335PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab
Hebei Medical University Fourth Hospital
Phase 4
40
Shijiazhuang
2025-07-01
Recruiting
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
NCT07434063Neutropenia
Hebei Medical University Fourth Hospital
Observational
200
Shijiazhuang
2025-06-18
Recruiting
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer๏ผˆNeo-Color๏ผ‰
NCT06949111Colon Cancer
Hebei Medical University Fourth Hospital
Phase 2
128
Shijiazhuang
2025-05-15
Recruiting
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
NCT06949098Rectal Cancer Stage I
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-05-15
Not yet open
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
NCT06903871Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Hebei Medical University Fourth Hospital
Phase 2
190
Shijiazhuang
2025-04-01
Not yet open
Tislelizumab in Combination with Chemotherapy ยฑ Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.
NCT06851819Small Cell Lung Cancer Extensive Stage
Hebei Medical University Fourth Hospital
Phase 2
64
Shijiazhuang
2025-03-01
Recruiting
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
NCT07179900Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-03-01
Not yet open
Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
NCT06681285Esophageal Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
51
Shijiazhuang
2024-11-01
Recruiting
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
NCT05578053Breast Cancer
Hebei Medical University Fourth Hospital
Observational
420
Shijiazhuang
2024-09-13
Recruiting
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
NCT06435260Pancreatic Cancer
Hebei Medical University Fourth Hospital
Phase 2
30
Shijiazhuang
2024-08-01
Recruiting
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
NCT07635342HER2-positive Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2
182
Shijiazhuang
2024-04-30
Recruiting
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
NCT06646588Esophageal Neoplasms
Hebei Medical University Fourth Hospital
Phase 2
67
Shijiazhuang
2024-04-01
Active, closed
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
NCT06210971Rectal Cancer
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2024-02-01
Recruiting
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
NCT06217185HER2-positive Breast Cancer, Advanced Breast Cancer
Hebei Medical University Fourth Hospital
Phase 4
100
Shijiazhuang
2024-01-02
Recruiting
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
NCT06184698Colorectal Cancer
Hebei Medical University Fourth Hospital
Phase 2
173
Shijiazhuang
2024-01-01
Recruiting
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer ๏ผˆEBC๏ผ‰
NCT06107673Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2
144
Shijiazhuang
2023-09-30
Recruiting
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
NCT06371482SCLC, Limited Stage
Hebei Medical University Fourth Hospital
Phase 2
58
Shijiazhuang
2023-06-01
Recruiting
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
NCT06056115Lung Adenocarcinoma
Hebei Medical University Fourth Hospital
Not applicable
20
Shijiazhuang
2023-05-01
Recruiting
Minimally Residual of Esophageal Cancer 001
NCT05952661Esophageal Carcinoma, Minimal Residual Disease
Hebei Medical University Fourth Hospital
Observational
56
Shijiazhuang
2023-02-22
Recruiting
Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors
NCT07490236Trilaciclib, CDK4/6-dependent Solid Tumors
Hebei Medical University Fourth Hospital
Phase 1
100
Shijiazhuang
2023-01-01
Recruiting
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
NCT05241028Non-small Cell Lung Cancer
Hebei Medical University Fourth Hospital
Phase 2
80
Shijiazhuang
2022-05-01
Recruiting
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
NCT05525767Solid Tumor
Hebei Medical University Fourth Hospital
Phase 4
75
Shijiazhuang
2022-03-31
Recruiting
Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer
NCT06375798Breast Cancer, HER2-negative Breast Cancer
Hebei Medical University Fourth Hospital
Observational
620
Shijiazhuang
2020-11-19
Active, closed
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
NCT04290793Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3
113
Shijiazhuang
2020-03-01
Recruiting
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
NCT04138719Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
Hebei Medical University Fourth Hospital
Phase 2
520
Shijiazhuang
2019-11-20
Recruiting
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
NCT04159142Triple Negative Breast Cancer, Nab-paclitaxel
Hebei Medical University Fourth Hospital
Phase 2
414
Shijiazhuang
2019-11-20
Recruiting
Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT03964753Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
202
Shijiazhuang
2019-04-24
Active, closed
The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC๏ผ‰
NCT06828718Esophageal Carcinoma
Hebei Medical University Fourth Hospital
Observational
1,000
Shijiazhuang
2015-01-01
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shijiazhuang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in Shijiazhuang that also match the filters currently applied.

How many clinical trials are recruiting in Shijiazhuang?

29 of the 43 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shijiazhuang), 43 studies
PhaseStudiesRecruitingShare
Phase 2281965.1%
Observational7616.3%
Phase 4327%
Phase 1214.7%
Phase 2/3204.7%
Not applicable112.3%

Most active sponsors

Lead sponsors with the most studies (Shijiazhuang)
Lead sponsorStudiesRecruiting
Hebei Medical University Fourth Hospital4329
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.